{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:04:29Z","timestamp":1790798669479,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Herein, we report a food\u2010effect study of vonoprazan, an oral potassium\u2010competitive acid blocker. In a phase 1, randomized, open\u2010label, crossover study, healthy subjects received a single 20\u2010mg dose of vonoprazan either following an overnight fast or 30 minutes after a high\u2010fat breakfast. Plasma vonoprazan levels were determined at 0 hour and at 17 subsequent assessment points up to 48 hours after dosing. After a 5\u2010day washout, subjects received a second 20\u2010mg vonoprazan dose in the alternative fed\/fasted state (identical process repeated). Twenty\u2010four subjects completed the study. Vonoprazan exposure was not meaningfully affected by food. Geometric mean ratios for maximum concentration, area under the concentration\u2010time curve from time 0 to 24 hours, and area under the plasma concentration\u2013time curve extrapolated to infinity obtained under fed and fasting conditions were 1.05 (90% confidence interval, 0.98\u20101.12), 1.13 (1.09\u20101.18), and 1.15 (1.11\u20101.19), respectively. Four subjects experienced 6 adverse events that were all mild and considered unrelated to the study drug. Vonoprazan can be administered without regard to food intake.<\/jats:p>","DOI":"10.1002\/cpdd.1009","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T03:20:10Z","timestamp":1629861610000},"page":"278-284","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The Effect of Food on the Pharmacokinetics of the Potassium\u2010Competitive Acid Blocker Vonoprazan"],"prefix":"10.1002","volume":"11","author":[{"given":"Darcy J.","family":"Mulford","sequence":"first","affiliation":[{"name":"Research and Development, Phathom Pharmaceuticals  Buffalo Grove Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Leifke","sequence":"additional","affiliation":[{"name":"Research and Development, Phathom Pharmaceuticals  Buffalo Grove Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hibberd","sequence":"additional","affiliation":[{"name":"Research and Development, Phathom Pharmaceuticals  Buffalo Grove Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Tennessee Health Science Center  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30408-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02339.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.153"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02945.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01024.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300318t"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623308320802"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01544.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2012.04.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31803233b7"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.09.33"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1214714"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0326-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17745776"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1203505"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170274"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.179556"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.02.009"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.185314"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02911.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00829.x"},{"key":"e_1_2_7_25_1","first-page":"S29","article-title":"Shortcomings of the first\u2010generation proton pump inhibitors","volume":"13","author":"Tytgat GN","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00433-2"},{"key":"e_1_2_7_27_1","first-page":"1015","article-title":"A validated simultaneous quantification method for vonoprazan (TAK\u2010438F) and its 4 metabolites in human plasma by the liquid chromatography\u2013tandem mass spectrometry","author":"Yoneyama T","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12452"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13325"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15641"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:18:39Z","timestamp":1692663519000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/cpdd.1009"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1009","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"2021-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}